Q-omics provides the consensus-scored ARMC4 profile across patient tissues and cancer cell-line models. ARMC4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ARMC4 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, ARMC4 RNA expression shows 15,553 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, LUSC, and TGCT as cancer lineages where ARMC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMC4 survival associations across molecular data types. ARMC4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMC4 RNA expression–survival associations across cancer types. High ARMC4 expression shows unfavorable associations in BLCA and LUAD, but favorable associations in BRCA, PAAD, MESO and CESC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ARMC4 RNA expression.
This table summarizes ARMC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARMC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMC4 shows lower tumor expression in LUSC, BLCA, LUAD, STAD and UCEC and higher tumor expression in KICH. The LUSC box plot shows higher ARMC4 RNA expression in normal versus tumor tissue (log2 FC = −2.035, t-test p < 0.001).
This table shows molecular features associated with ARMC4 in patient tissues and cancer cell lines. In patient samples, ARMC4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ARMC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
